环孢素A联合方案治疗低危骨髓增生异常综合征  

Clinical Effect of Cyclosporin a Combined with Hematopoietic Growth Factor for Low-risk Myelodysplastic Syndrome

作　　者：杨志刚[1] 梁亮[1] 吴东红[1] 吴国才[1] 李庆华[1] 熊丹[1] 

机构地区：[1]广东医学院附属医院血液科,湛江市524001

出　　处：《中华全科医学》2008年第8期784-785,共2页Chinese Journal of General Practice

摘　　要：目的探讨环孢素A(CsA)联合造血生长因子治疗低危骨髓增生异常综合征(MDS)的临床疗效。方法用CsA联合造血生长因子治疗低危骨髓增生异常综合征患者30例,定期观察患者外周血象和骨髓象变化,并随诊观察远期疗效。结果30例患者治疗总有效率为80.0%(24/30)。70.0%(21/30)患者血液学指标改善并摆脱输血依赖,全部患者无严重毒副反应出现。结论CsA联合造血生长因子治疗低危骨髓增生异常综合征疗效可靠,耐受性好。Objective To explore the clinical result of cyclosporin A（CsA） combined with hematopoietic growth factor in the treatment of low-risk myelodysplastic syndrome（MDS）. Methods 30 cases with low-risk MDS were treated with CsA and hematopoietic growth factor. The changes of peripheral blood cells and bone marrow were observed regularly. A follow-up observation for long-term therapy effect was carried out. Results The total effective rate of 30 patients was 80. 0% （24/30）. No serious sideeffects occurred in all treated patients. The anemia in 70.0% （21/30） patients was improved and these transfusion-dependent patients achieved transfusion independence. Conclusions The treatment of low-risk MDS by CsA combined with hematopoietic growth factor is safe and effective.

关 键 词：环孢素A 造血生长因子 骨髓增生异常综合征 

分 类 号：R551.31[医药卫生—血液循环系统疾病]